DOP033 Multiple advanced therapies in combination for the treatment of inflammatory bowel disease - a bi-national registry

Journal of Crohn s and Colitis 2026

View at publisher
Authors: J Chetwood, P H Le, S C Wei, H Y Wu, Crispin Corte, Daniel Lightowler, Robert B. Gilmore, S Chin, Mayur Garg, S Bahmani Kashkooli, Ziheng Calvin Xu, E K Wright
+16 more M P Sparrow, J O’Donnell, Peter J. Lewindon, Kavitha Subramanian, J Huang Fu, G T Moore, Deloshaan Subhaharan, Waled Mohsen, Zhi Tan, Lena W. Y. Thin, M Ghali, S Ghaly, Peter P. De Cruz, S W Lo, Sudarshan Paramsothy, R Leong
DOI: 10.1093/ecco-jcc/jjaf231.070
Cited by: 1

Abstract

Abstract Background There is increasing interest in using ≥2 advanced therapies in inflammatory bowel disease (IBD) for refractory disease, multi-organ involvement and concurrent autoimmune conditions. However, data on prescribing practices are extremely limited, and comparative efficacy and safety remain largely unknown. Prior meta-analyses have included

Fields of Study & Subjects

Inflammatory Bowel Disease Biosimilars and Bioanalytical Methods Microscopic Colitis

Publication details

Journal / source
Journal of Crohn s and Colitis
Publisher
Oxford University Press (OUP)
Volume
20
Issue
Supplement_1
Publication date
1 January 2026
Language
EN